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Glomerular heparan sulfate alterations: Mechanisms and rele- During glomerular ultrafiltration, the barrier restrict-
vance for proteinuria. Heparan sulfate (HS) is the anionic ing the passage of plasma proteins into the urine is the
polysaccharide side chain of HS proteoglycans (HSPGs) pres- glomerular capillary wall (GCW). The GCW consists ofent in basement membranes, in extracellular matrix, and on
the fenestrated endothelium, the glomerular basementcell surfaces. Recently, agrin was identified as a major HSPG
membrane (GBM), and the foot processes of the glomer-present in the glomerular basement membrane (GBM). An
increased permeability of the GBM for proteins after digestion ular visceral epithelial cells or podocytes with in-between
of HS by heparitinase or after antibody binding to HS demon- the slit diaphragms. The fenestrae of the endothelial cells
strated the importance of HS for the permselective properties allow direct contact of blood with the GBM and hardlyof the GBM. With recently developed antibodies directed
restrict passage of macromolecules [1]. Some data showagainst the GBM HSPG (agrin) core protein and the HS side
that podocytes are involved in the permeability of thechain, we demonstrated a decrease in HS staining in the GBM
in different human proteinuric glomerulopathies, such as sys- GCW. Cross-linking of the integrin receptors for extra-
temic lupus erythematosus (SLE), minimal change disease, cellular matrix (ECM) components on the podocyte re-
membranous glomerulonephritis, and diabetic nephropathy,
sulted in a decreased adhesion of podocytes to the GBMwhereas the staining of the agrin core protein remained unal-
and an increased passage of macromolecules in vitro [2].tered. This suggested changes in the HS side chains of HSPG
in proteinuric glomerular diseases. To gain more insight into Furthermore, in saponin-induced podocyte injury in the
the mechanisms responsible for this observation, we studied single nephron model, passage of albumin through the
GBM HS(PG) expression in experimental models of protein- GCW was localized to regions of detachment [3]. An
uria. Similar HS changes were found in murine lupus nephritis,
injection of a monoclonal antibody directed against aadriamycin nephropathy, and active Heymann nephritis. In
component of the slit diaphragm resulted in an acutethese models, an inverse correlation was found between HS
staining in the GBM and proteinuria. From these investiga- massive proteinuria [4, 5]. Nevertheless, the GBM is
tions, four new and different mechanisms have emerged. First, probably the most important component of this barrier
in lupus nephritis, HS was found to be masked by nucleosomes and restricts the passage of macromolecules by both sizecomplexed to antinuclear autoantibodies. This masking was
and charge. Tracer studies have shown that the GCWdue to the binding of cationic moieties on the N-terminal parts
behaves like a sieve, through which small molecules,of the core histones to anionic determinants in HS. Second, in
adriamycin nephropathy, glomerular HS was depolymerized such as inulin, can pass without restriction, whereas with
by reactive oxygen species (ROS), mainly hydroxyl radicals, increasing molecular size, the passage into the urinary
which could be prevented by scavengers both in vitro (exposure space decreases progressively [6]. Studies using dextranof HS to ROS) and in vivo. Third, in vivo renal perfusion of
fractions with similar molecular radii carrying either neu-purified elastase led to a decrease of HS in the GBM caused
tral, anionic (dextran sulfate), or cationic (diethylamino-by proteolytic cleavage of the agrin core protein near the at-
tachment sites of HS by the HS-bound enzyme. Fourth, in ethyl dextran) charges showed an enhanced permeability
streptozotocin-induced diabetic nephropathy and during cul- to cationic but a restricted permeability to anionic dex-
ture of glomerular cells under high glucose conditions, evidence
tran fractions [6–8].was obtained that hyperglycemia led to a down-regulation of
The GBM is organized as a network of fibrils or chordsHS synthesis, accompanied by a reduction in the degree of HS
sulfation. forming a small-meshed sieve. The composition of the
GBM is different from most other BMs. Many compo-
nents are present in the GBM, the most abundant areKey words: glomerular basement membrane, protein permeability,
extracellular matrix, podocytes, heparan sulfate proteoglycans. type IV collagen chains a3, a4, and a5, various laminin
isoforms, especially laminin 11 (composed of a5b2g1Received for publication February 19, 1999
laminin chains) and heparan sulfate proteoglycansand in revised form May 28, 1999
Accepted for publication June 18, 1999 (HSPGs) [9–13]. The main BM HSPGs that have been
characterized until now are perlecan, agrin, and recentlyÓ 2000 by the International Society of Nephrology
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collagen XVIII, which have a different localization in ing [58–61]. Apart from its role in the charge-dependent
permeability, HS may also play a role in the size-depen-the glomerulus. Perlecan and collagen XVIII are most
abundant in the mesangial matrix, whereas agrin is a dent permeability. HS is able to bind other components
of the GBM, such as collagen and laminin, whereas themajor HSPG in the GBM. The glomerular localization
and basic characteristics of these BM HSPGs are shown core protein of agrin contains a laminin-binding site and
probably contributes to the molecular architecture ofin Figure 1.
Proteoglycans (PGs) consist of a core protein to which the GBM [29, 62–65].
Besides the role in the glomerular filtration, HS mayGAG side chains are attached. For HSPG, this GAG
side chain is HS. HS contains many negative charges, have several other functions in the GBM. It functions
as a anchorage molecule and storage depot for variouswhich are important determinants for the charge-depen-
dent permeability of the GBM. HS is an unbranched chain proteins, such as platelet-derived growth factor, basic
fibroblast growth factor-2 and its receptor, antithrombinof repeating disaccharide units, which contain an uronic
acid (glucuronic or iduronic acid) and the aminosugar III, hepatocyte growth factor, interferon-g, lipoprotein
lipase, and platelet factor 4 [44, 66]. HS has anticoagulantglucosamine. After formation of the precursor molecule
heparosan, extensive modifications take place starting properties, preventing coagulation at the endothelial sur-
face of the GBM [67]. Moreover, HS inhibits mesangialwith N-deacetylation/N-sulfation of the glucosamine res-
idue, followed by C-5 epimerization of glucuronic acid cell proliferation [68–71]. Therefore, it may affect in-
flammation, mesangial proliferation and expansion, andinto iduronic acid, and O-sulfation at various positions
[36]. For most reactions, several isoenzymes exist that other processes involved in glomerular pathology.
In different human proteinuric glomerulopathies, suchhave subtle differences in substrate-specificity; further-
more, these reactions run incompletely, leading to a great as systemic lupus erythematosus (SLE), minimal change
disease, membranous glomerulonephritis, and diabeticvariation in the degree of sulfation along the stretch of
the side chains. Because of the sequential order of the nephropathy, we demonstrated with antibodies directed
modification reactions and the substrate specificity of the against the agrin core protein and the HS side chain [72,
enzymes involved, the initial distribution of N-sulfate 73] a decrease in HS staining in the GBM, whereas the
groups will greatly determine the location of iduronic staining of the agrin core protein remained unaltered
acid residues and O-sulfate groups. This results in a block- [58–61]. This suggested that in certain forms of glomeru-
like structure in which alternating N-acetylated, mixed lar pathology, changes occur in the HS side chains of
N-acetylated/N-sulfated and N-sulfated (heparin-like) agrin that may be related to the development of protein-
domains are found (Fig. 2) [37–42]. Certain functions uria. This review focuses on four different mechanisms
of HS are restricted to specific sulfation patterns, for that are identified up to now for these changes in the
example, the binding to antithrombin III or fibroblast HS polysaccharide side chain, masking by immune com-
growth factor-2 [43–46]. The presence of sulfate groups plexes, depolymerization by radicals, degradation by
and carboxyl groups is responsible for the negative charge proteolytic enzymes or metabolically-induced biochemi-
of HS at physiological pH. The functional relevance of cal changes in the HS structure.
the HS modification is shown by knockout mice lacking
the enzyme HS 2-O-sulfotransferase, responsible for
MASKING OF HEPARAN SULFATE BY2-O-sulfation of HS. These mice do not develop kidneys
IMMUNE COMPLEXESand die shortly after birth [47]. This enzyme deficiency
Systemic lupus erythematosus is an autoimmune dis-has consequences for the interaction of HS with other
ease characterized by the formation of autoantibodies,ECM components, as well as with growth factors, which
mainly directed against nuclear antigens. Currently, it isboth are necessary for normal kidney development.
clear that this autoimmune response is T-cell dependentThe relevance of HS for the charge-dependent perme-
and antigen driven. A major candidate autoantigen forability is documented by several experimental data [48,
this response is the nucleosome, the building unit of49]. First, enzymatic digestion of HS by heparitinase
chromatin, consisting of histones and DNA [74]. Besidescaused an enhanced permeability of the GBM for native
serving as an immunogen for T- and B-cell responses,ferritin and albumin [50, 51]. Second, an acute, selective
nucleosomes are also important for the development ofproteinuria could be induced in rats by a single intrave-
glomerulonephritis in SLE. The observation that anti-nous injection of a monoclonal antibody directed against
nuclear antibodies could bind to HS started investiga-GBM HS [52]. Third, a reduction in GBM HS-associated
tions on the mechanism for the development of glomeru-anionic sites was demonstrated with cationic probes in
lonephritis [74–76]. It was shown that the binding ofseveral human and experimental proteinuric glomerulo-
antinuclear antibodies to HS was not due to cross-reactivepathies [53–57]. Fourth, in several human and experi-
binding, as initially thought, but was mediated by nucleo-mental glomerulopathies, an inverse correlation has
been found between albuminuria and the GBM HS stain- somes [77]. Renal perfusion studies made it clear that
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Fig. 2. Schematic representation of an he-
paran sulfate proteoglycan (HSPG) molecule.
nucleosomes could also mediate the binding of anti- to the loss of HS from the GBM, as quantitation of
HS isolated from glomeruli with an absent HS stainingnuclear antibodies to the GBM in vivo [78]. The cationic
histone part of the nucleosome is responsible for the bind- revealed a normal HS content [59]. Nucleosome-com-
plexed autoantibodies were shown to inhibit dose depen-ing to the anionic HS in the GBM [79], as evidenced by
a number of observations. First, the removal of HS from dently the binding of anti-HS monoclonal antibody (mAb)
to HS in an ELISA system, whereas noncomplexed auto-the GBM by renal perfusion with the HS-degrading en-
zyme heparinase partly prevented binding of subsequently antibodies had no effect. A similar mechanism seemed
to occur in vivo, as a significant correlation was foundperfused nucleosome antinuclear antibody complexes
[78]. Second, masking of the cationic charges on histones in human lupus nephritis between decrease in HS stain-
ing of the GBM and histone deposition (Fig. 3) [84].in the nucleosome by antihistone antibodies decreased
the nephritogenicity of nucleosome autoantibody com- Furthermore, treatment with heparin(oids), which pre-
vented immune complex deposition in the GBM and theplexes [80]. Third, treatment of MRL/lpr mice with hepa-
rin or noncoagulant heparinoids prevented the deposition development of glomerulonephritis, also prevented the
loss of HS staining [81].of complexes in the GBM and ameliorated glomerulone-
phritis [81]. That the HS side chains serve as the binding Therefore, in SLE nephritis and possibly also in other
glomerular diseases in which immune complex deposi-sites within the HSPG molecule was already suggested by
the observation that the formation of immune complexes tion in the GBM is known to play a role in the pathogene-
sis, this deposition may lead to masking of HS and itswithin the GBM in (NZB 3 NZW) F1 mice was not
influenced by the administration of antibodies directed anionic charges, resulting in an enhanced permeability
of the GBM for macromolecules. Further research mustagainst the core protein of GBM HSPGs [82]. The rele-
vance of nucleosome-mediated autoantibody binding for be accomplished to reveal which domains of the HS
molecule serve as ligands for these immune complexes.lupus nephritis in mice and patients with SLE was sub-
stantiated by the identification of antinucleosome anti-
bodies in glomerular eluates in murine lupus [83] and
DEPOLYMERIZATION OF HEPARAN
the presence of nucleosomes within glomerular deposits
SULFATE BY RADICALS
in patients with diffuse proliferative (World Health Or-
Generation of oxygen and nitrogen radicals inganization class IV) lupus nephritis [84]. Using mono-
the glomerulusclonal antibodies against the HSPG core protein and HS
side chain [72], we found a strong decrease or even total The first cells identified in glomerulopathies to produce
radicals were infiltrating phagocytes [polymorphonu-absence of staining for the HS side chain in patients with
lupus nephritis, whereas the staining for the HSPG core clear neutrophils (PMNs), monocytes, and macrophages],
which generate radicals upon activation. Therefore, inprotein was unaltered [58]. This observation extended
previous reports in which a decrease of anionic sites within forms of glomerulonephritis in which inflammatory cells
infiltrate the glomerulus, such as anti-GBM nephritisthe GBM was reported in lupus nephritis [85, 86]. Bind-
ing of neutrophil- or platelet-derived cationic proteins (discussed later in this article), reactive oxygen species
(ROS) can locally be released by infiltrating phagocytes.to the GBM was already suggested as a mechanism for
the decreased number of anionic sites in lupus nephritis Later it was shown that intrinsic renal cells are also
able to generate radicals under various circumstances.[87, 88]. The mechanisms responsible for the decrease
in HS staining were further analyzed in the MRL/lpr Glomerular epithelial cells in culture produce ROS after
exposure to adriamycin [89], puromycin aminonucleo-lupus mouse model. In these mice, the decrease in HS
staining correlated with Ig deposits in the GBM and side [90], and adenosine 59-triphosphate (ATP) [91]. Cul-
tured mesangial cells generate ROS during phagocytosisalbuminuria. This decrease in staining of HS was not due
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as interleukin-1 (IL-1) and tumor necrosis factor-a
(TNF-a) [95]. During ischemia and subsequent reperfu-
sion, ROS are produced by endogenous xanthine oxidase
[96]. In the isolated perfused kidney, a partial ischemic
system, indeed an increase in xanthine oxidase expres-
sion was observed [97]. Besides ROS, vascular endothe-
lial cells, PMNs, and monocytes can serve as a source of
nitric oxide (NO).
Various processes can lead to the formation of O22,
such as reperfusion after ischemia, redox cycling of cer-
tain drugs, and high-energy irradiation. Also during in-
flammation, invading immune cells can form and excrete
O22 (Fig. 4). Upon an initial formation of superoxide
anion (O22), a cascade of reactions can occur. O22 can
react with H2O and form H2O2, and in the presence of
metal ions, such as Fe31, hydroxyl radicals ( •OH), can
be formed in the so-called Haber–Weiss reaction. These
hydroxyl radicals can damage proteins, carbohydrates,
membrane phospholipids, and DNA [69, 70, 98, 99]. Fur-
thermore, myeloperoxidase (MPO) can halogenate pro-
teins by catalyzing the reaction of H2O2 with one of the
halides Cl2, I2, or Br2 forming hypohalous acids (HOCl,
HOI, or HOBr). Hypohalous acids are able to damage
proteins by halogenation [100]. NO can react with O22
to form peroxynitrite (ONOO2), which is able to cause
nitration of tyrosine residues in proteins and lipid peroxy-
dation [101–103].
Radicals increase glomerular permeability
There is compelling evidence that radicals increase
the permeability of the glomerulus and the GBM both
in vitro and in vivo, as summarized in Table 1. In several
models of glomerulopathy, oxygen radicals have been
shown to be involved in the development of albuminuria.
Adriamycin nephropathy and puromycin aminonucleo-
side nephropathy in rats are experimental models for
the nephrotic syndrome and are characterized by heavy
albuminuria and hypoalbuminemia [122–124]. Adriamy-
cin can be subjected to redox-cycling by which superoxide
(O22) is formed [125–127]. Puromycin aminonucleoside
is metabolically degraded to hypoxanthine, which can
serve as a substrate for xanthine oxidase, resulting in
Fig. 3. Glomerular capillary wall staining of the agrin core protein, O22 formation. In rats with passive Heymann nephritis,heparan sulfate (HS), and histones in human systemic lupus erythrema-
the formation of immune complexes and activation oftosus (SLE) nephritis. Immunofluorescence with anti-grin core protein
mAb JM72 (A) anti-HS side chain mAb JM403 (B) in a double staining, complement are thought to be involved in ROS forma-
and antihistone 3 polyclonal antiserum (C) in a patient with lupus tion and development of proteinuria. In inflammatory
nephritis (magnification 3350). Reproduced with permission (A and
glomerular diseases, ROS are produced in the mitochon-B) from van den Born et al and the International Society of Nephrology
[58] and (C) from Van Bruggen et al and Nephrol Dial Transplant [84]. dria of PMNs via cytochrome b558, which is part of the
NADH/NADPH oxidoreductase complex of the respira-
tory burst. In rats with passive Heymann nephritis, it is
suggested that in response to immune complex formation
and complement activation, glomerular epithelial cells ex-of extracellular material [92], after complement activa-
tion at the cell surface, after interaction with the C5b-9 press enzymes of the respiratory burst, ROS are generated
resulting in damage of the GBM and proteinuria [128].membrane attack complex [93], after binding of immune
complexes [94], and after stimulation by cytokines such In the heterologous phase of passive anti-GBM nephritis,
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Fig. 4. Major reactions involved in the for-
mation of oxygen/nitrogen radicals.
Table 1. Mechanisms and consequences of radical generation in various experimental model systems and glomerular diseases
Produced radical Experimental model Scavengers Mechanism Consequence
O22 Isolated glomeruli [104] TNFa release by activated GBM permeability"
macrophages/PMNs [105]
•OH Renal H2O2 perfusion CAT, DFO proteinuria"
[106]
•OH ADR nephropathy SOD, DMTU O22 release by redox cycling of proteinuria"
[61, 107, 108] ADR [125–127]
•OH PAN [109–111] SOD, DMTU, DFO, Na-benzoate, O22 formation via degradation proteinuria"
allopurinol, a-tocopherol 1 of hypoxanthine
ascorbic acid
•OH PHN [112, 113] DMTU, sodium benzoate, DFO increased cyt b558 expression by proteinuria"
podocytes [128]
•OH Anti-GBM [114,115] CAT, DMSO activated PMNs albuminuria"
HOCl In vitro GBM filtration [116] GBM permeability"
HOCl In vitro GBM [117] MPO-H2O2-halide release by GGM degradation
activated PMNs
Hypohalous acids Isolated glomeruli [104, 118] activated macrophages/PMNs GBM permeability"
Hypohalous acids Renal perfusion MPO-H2O2 GBM halogeneation GBM permeability"
[119]
Hypohalous acids Renal perfusion con A/anti- PMN activation, GBM haloge- proteinuria"
con A [120] nation
ONOO2 MPO immunization, perfu- PMN/monocyte influx ONOO2-modified
sion with lysosomal PMN proteins
extract and H2O2 [121]
Abbreviations are: ADR, adriamycin; PAN, puromycin aminonucleoside; PHN, passive Heymann nephritis; GBM, glomerular basement membrane; MPO,
myeloperoxidase; con A, concanavalin A; PMN, polymorphonuclear neutrophil; CAT, catalase; DFO, deferoxamine; SOD, superoxide dismutase; DMTU, dimethylthi-
ourea.
activated PMNs attached to the GBM secrete ROS and this can be also prevented by treatment with scavengers.
Only few data are available on the pathogenic role oflysosomal enzymes, which are responsible for the glomer-
ular damage. In Table 1, the effects of hypohalous acids NO and peroxynitrite in glomerular permeability.
and peroxynitrite on glomerular permeability are also
Radicals depolymerize heparan sulfatesummarized. Taken together, several in vitro and in vivo
experiments indicate that hydroxyl radicals are the most The increase of the permeability of the GBM by radi-
cals can be caused by damage of many macromoleculesharmful in affecting normal glomerular permselectivity.
Furthermore, the MPO-H2O2-halide system has the ca- in the GBM, including degradation of HS. Several inves-
tigators have reported the susceptibility of HS, otherpacity to disturb glomerular filtration, but it is unclear if
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GAGs, and PGs to radicals in vitro [61, 129–136]. All of mechanism by which radicals can affect the permeability
properties of the GBM.these studies point to the hydroxyl radical as the most
harmful ROS. The susceptibility of different GAGs to
Physiological significance of the susceptibility ofdepolymerization by ROS is dependent on the degree
heparan sulfate to reactive oxygen speciesof sulfation. High-sulfated GAGs are more resistant to
depolymerization than low-sulfated or nonsulfated GAGs In vitro experiments indicate that heparin and hyaluro-
nic acid act as antioxidants and decoy molecules [143–[130, 131, 134]. HS in the GBM is composed of mixed high-
and low-sulfated regions and contains large N-acetylated 145]. This is probably the mechanism by which heparin
treatment of patients with diabetic nephropathy resultsstretches [137], suggesting that degradation will predomi-
nantly occur in these low-sulfated or nonsulfated parts. in a decrease of albuminuria [146, 147]. In adriamycin
nephropathy, streptozotocin (STZ)-induced diabetic ne-The isolated perfused kidney, in which ROS are known
to be produced as result of the ischemia, is also associated phropathy in rats and murine lupus nephritis heparin
treatment prevented the loss in HS-associated anionicwith an increased protein excretion and partial degrada-
tion of HS [138]. Both of these effects can be prevented sites in the GBM and ameliorated proteinuria [81, 148–
150]. This suggests that HS can also serve as an antioxi-by the addition of allopurinol or a mixture of mannitol,
superoxide, and catalase, again suggesting that hydroxyl dant in the GBM to protect other molecules from degra-
dation. By depolymerization of HS, oligosaccharides areradicals are responsible for HS degradation and protein-
uria in this model [97]. This production of ROS during released, which could have pathophysiological relevance,
although this is rather speculative. Because HS can func-ischemia may be the result of the release of xanthine
oxidase into the circulation, as shown in the hemorrhagic tion as an anchorage and storage molecule for growth
factors, such as fibroblast growth factor-2 [45, 46], theseshock model of ischemia reperfusion. In this model, xan-
thine oxidase is shown to bind to GAGs of vascular cells, can be set free upon depolymerization of HS and activate
glomerular epithelial and/or mesangial cells. In addition,with subsequent degradation of HS [96]. Also, other
studies show xanthine oxidase binding to HS, which lo- the release of HS oligosaccharides could impair local
anticoagulation and may lead to clogging of the GBMcalizes the enzyme to cell surfaces and increases catalytic
activity [139, 140]. We have shown that the HS polysac- [67]. Further research is needed to answer these questions.
charide side chains of rat agrin in vitro can be depolymer-
ized by ROS produced by the hypoxanthine-xanthine
CLEAVAGE OF HS(PG) BY ENZYMES
oxidase system in the presence of Fe31, whereas the
Neutral serine proteinasesPG core protein remained intact. This depolymerization
could be prevented by superoxide dismutase and dimeth- Among the enzymes that are released by activated
PMNs are the cationic neutral serine proteases elastaseylthiourea, indicating that •OH were responsible for this
effect (Fig. 5A) [61]. In adriamycin nephropathy in rats, and cathepsin G. Infusion of elastase or cathepsin G
results in the binding of these cationic proteinases to thea model in which ROS are known to play a role [127],
we found that the degree of albuminuria was correlated GBM (probably to the anionic HS) and subsequently to
proteinuria [151]. The involvement of these proteinaseswith a decrease in staining of GBM HS, whereas the
staining for the agrin core protein remained normal. in the development of albuminuria is further substanti-
ated by the observation that beige mice, which have aBoth albuminuria and the decrease in GBM HS staining
could be partially prevented by treatment of the rats deficiency for PMN elastase and cathepsin G, do not
develop albuminuria after the administration of anti-with dimethylthiourea, which supports the role of •OH
in the depolymerization of HS and the development of GBM antibodies, although a comparable influx of PMNs
to control mice is seen [152]. Furthermore, in vivo perfu-albuminuria in vivo (Fig. 5 B, C) [61].
Besides to ROS, NO gas or NO derived from cultured sion of elastase in rats results in proteinuria and decrease
in GBM HS staining and to a lesser extent of agrin coreendothelial cells can also degrade HS and heparin in
vitro via the formation of HNO2 at a pH below 5 [141]. protein staining, whereas other ECM components such
as S-laminin, fibronectin, and collagen type IV were notBecause NO is produced by endothelial cells, PMNs
and monocytes after inflammatory stimulation and these affected [153]. In vitro experiments showed that elastase,
which is highly cationic at physiological pH, can bind toinflammatory cells create local acidic conditions, it may
be involved in HS depolymerization and the develop- the anionic HS. Next, elastase cleaves agrin near the HS
attachment sites, and HS side chains bound to smallment of albuminuria in glomerular inflammation. NO
can react with superoxide to form peroxynitrite, which peptide fragments are released [132, 153]. A comparable
result was obtained by intratracheal instillation of elas-is probably also capable of GAG degradation, as it is
shown to degrade hyaluronic acid [142]. tase in rats, which leads to pulmonary emphysema. The
BMs in alveoli showed a decrease in HS staining and toThese studies clearly show that HS is susceptible to
depolymerization by radicals, providing an important a lesser extent of the agrin core protein staining, whereas
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no alteration was observed for laminin, fibronectin, and
type IV collagen [154]. Also, endothelial cell-surface
HSPG is susceptible to PMN-derived elastase and to
human elastase [155]. The role of elastase is further con-
firmed by the observation that treatment of rats with
anti-GBM nephritis with an inhibitor of elastase results
in a reduced proteinuria, despite an equal amount of
IgG binding [156]. These studies show that although
elastase (and probably also cathepsin G) is not a specific
HSPG-degrading proteinase, it has a relative preference
to cleave HSPGs above other ECM components, thereby
inducing proteinuria [153, 154].
Heparan sulfate-specific endoglycosidases
The HS-specific endoglycosidase heparanase can be
released during inflammation by activated PMNs and
platelets, leading to HS degradation [157, 158]. Also,
activated macrophages, mononuclear cells, mast cells,
and T cells are able to release a heparanase that can
cleave and release HS from endothelial cell-derived
ECM [159–162]. Finally, a synergistic action is suggested
for heparanase and several other enzymes. The effect of
heparanase can be enhanced by elastase. Probably, mi-
nor proteolysis of HSPG making the substrate more ac-
cessible to other enzymes is necessary for heparanase
for further degradation of HS [157, 158]. Other studies
show that several enzymes, such as plasminogen activa-
tor and thrombin, which themselves do not degrade HS,
can work synergistically with heparanase [163, 164]. This
suggests that during inflammation and activation of the
coagulation cascade, the activity of the released heparan-
ase is enhanced by enzymes formed during coagulation.
Taken together, these studies indicate that heparanases
released during inflammation are able to degrade HS
and could therefore play a role in increasing the perme-
ability of the GBM during inflammatory glomerulopa-
Fig. 5. (A) Effect of reactive oxygen species (ROS) on heparan sulfate
(HS) and heparan sulfate proteoglycans (HSPG) in vitro. Coated
HSPGs from rat GBM were incubated with hypoxanthine, xanthine
oxidase, and Fe31 in the presence of various concentrations of ·OH
scavenger dimethylthiourea, then ELISA was performed with anti-HS
mAb JM403 (d) or the goat anti-agrin core protein antibody BL31
(s). (B) Effect of ROS scavengers on albuminuria in adriamycin ne-
phropathy. Rats with adriamycin nephropathy were treated with either
dimethylthiourea (d), superoxide dismutase (n), or saline (h). *P ,
0.01 vs. saline, analysis of variance for repeated measurements. (C)
Effect of ROS scavengers on GBM HS staining in adriamycin nephropa-
thy. Indirect immunofluorescence on kidney sections of normal rats
( ) and rats with adriamycin nephropathy treated with either saline
(h), superoxide dismutase (j), or dimethylthiourea ( ). Indirect im-
munofluorescence was performed with anti-HS side chain mAbs JM403
(left) and KJ865 (right). Twenty-five glomeruli were scored on a scale
between 0 and 10, such that the maximal score is 250 arbitrary units
(AU). *P 5 0.03 versus saline-treated rats. Reproduced with permission
from Raats et al and J Biol Chem [61].
Raats et al: Glomerular HS and proteinuria 393
thies. The importance of these mechanisms remains to of diabetic nephropathy. Most of these studies have been
carried out in the STZ-induced diabetes model in thebe determined.
rat. Biochemical quantitation of HS in the GBM, glomer-
uli, or renal cortex revealed a decreased [176–179] or
CHANGES IN HEPARAN SULFATE
unaltered [166, 180] HS content in these rats. Studies on
PROTEOGLYCAN SYNTHESIS
HS synthesis in the GBM or glomeruli in this model by in
Besides masking, depolymerization and degradation vivo 35S-sulfate incorporation revealed either a decreased
of HS, there is evidence for a fourth mechanism that can [178, 179, 181] or normal [182, 183] synthesis of HS.
lead to a reduction of functional HS in certain glomerulo- Studies using 35S-sulfate incorporation in ex vivo systems
pathies: a changed biosynthesis that results in an abnor- (isolated perfused kidney) or in vitro (short-term culture
mal glomerular HS content and/or alterations in the of glomeruli) suggested a decreased HS synthesis [184,
structure or sulfation of HS. 185], although this is not found by all investigators [182].
As mentioned before, many investigators have studied A clear interpretation of these results is hampered by
the GBM distribution of HS-associated anionic sites in the use of different rat strains, differences in diabetes
human and experimental glomerulopathies by using cat- duration, the absence or incomplete description of the
ionic dyes such as ruthenium red, polyethyleneimine, development of a progressive diabetic nephropathy, and
poly-l-lysine, cationic ferritin, and cuprolinic blue. It is most importantly, by the use of different techniques to
assumed that each anionic site, visible as a granule or evaluate the HS content. A disadvantage of the incorpo-
filament (depending on the dye used), represents the ration studies is related to the rather indirect method to
equivalent of a proteoglycan (PG) monomer [165]. Thus, identify the individual GAGs by either GAG-degrading
a reduction in the number of GBM anionic sites might enzymes or nitrous acid treatment. In addition, it is
reflect a reduced HSPG content, whereas a change in stressed that the rate of HS synthesis yields no informa-
the size or morphology of the anionic sites is interpreted tion about the actual glomerular HS content and that
as a change in the HS structure (size/charge). Other the PG synthesis of isolated glomeruli in tissue culture
studies, however, show that changes in the number or is different from that in vivo [186]. Moreover, one should
appearance of anionic sites may also be related to bio- realize that GBM thickening and mesangial matrix
chemical changes in the surrounding ECM [166]. It is expansion contribute to a reduction in HSPG density,
clear that this methodology can only hint at changes in although the absolute HSPG content was not changed
HS content and/or structure and that immunohistochem- [187]. In a few reports, a semiquantitative analysis was
ical and biochemical analysis can provide more definitive performed on the mRNA content coding for perlecan
answers. in renal cortex or glomeruli of diabetic and control mice/
rats. In one study [188], a temporary decrease was found,
Glomerular heparan sulfate proteoglycan synthesis in which normalized after six months. In both other studies,
diabetic nephropathy no change in perlecan mRNA expression was found [189,
Functional studies on glomerular permeability in pa- 190]. It should be noted, however, that it is not perlecan
tients with insulin-dependent diabetes mellitus (IDDM), but agrin that is the most abundant HSPG in the GBM
using uncharged polydisperse dextrans or tracer mole- [14, 15]. Because perlecan is predominantly localized in
cules with equal molecular weight, but with different the mesangial matrix (Fig. 1), its relevance for glomerular
charges, indicated both an increased porosity of the filtration is highly questionable.
GBM, as well as a reduced charge-dependent permeabil-
Glomerular heparan sulfate structure inity, in all probability related to loss of GBM anionic
diabetic nephropathycharges [167–170]. Therefore, the significance of GBM
HSPG for the development of incipient and overt dia- In vitro studies have shown that the extent of biosyn-
betic nephropathy has been analyzed in several studies. thetic modification affecting the number, length, and sub-
A relative decreased GBM content of HS and HSPG stitution patterns of the modified domains, as well as
has been found in patients with IDDM [171–173]. We their position along the HS chain may differ among cell
found a decreased staining for HS in the GBM in kidney types [191], alter during proliferation [192], cell transfor-
biopsies from diabetes patients (both IDDM and non- mation [193–196], infection [197], age [198], differentia-
IDDM), which correlated with the fractional protein ex- tion [199–201], and in response to a variety of agents
cretion, whereas the GBM staining for the core protein [202–205]. As indicated at the beginning of this article,
of HSPG was unaltered [58, 60]. Others, however, also structural HS changes might have important conse-
found a decreased GBM staining for the core protein of quences for protein binding and other functions of HS.
HSPG in diabetic kidneys [174, 175]. Because of the With respect to diabetes, an undersulfation of HS has
obvious limitations of the study of human material, inves- been described in STZ-induced diabetes in the rat. Bio-
chemical analysis of liver HS purified from diabetic ani-tigations were also performed in experimental models
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Fig. 6. Schematic representation of the four described mechanisms leading to reduced heparan sulfate (HS) function. (A) Positively charged
amino acids in the N-terminal regions of the four core histones present in nucleosome-containing immune complexes bind to HS in the GBM,
thereby neutralizing the anionic charge of the GBM. (B) Oxygen and/or nitrogen radicals, formed during glomerular injury and/or inflammation,
are able to depolymerize HS, leading to loss of HS in the GBM. (C) By virtue of its positive charge, elastase binds to the HS side chains and
subsequently cleaves the HSPG core protein close to the HS attachment site. (D) Hyperglycemia can induce alterations via a reduction of the HS
synthesis by podocytes. Moreover, the degree of sulfation can be reduced, leading to a diminished GBM anionic charge.
mals showed an elution from a cation exchange column sulfation. Indeed, in hepatocytes and glomeruli of STZ-
at a lower salt concentration compared with control liver induced diabetic rats, a reduced activity of this enzyme
HS [206]. This indicates a lower negative charge density was found [190, 212, 213]. In conclusion, although not
(sulfation) of diabetic HS. Also, for glomerular HS, an found by all investigators, many studies in experimental
undersulfation was found, as indicated by lower sulfate- diabetes suggest a down-regulation of HS synthesis,
to-uronate ratio [180]. Biochemical analysis of radiola- which is accompanied by a reduction in the degree of
beled HS isolated from intestinal cells from diabetic and sulfation.
control rats showed a reduction of both N- and O-sul- Because the diabetic condition affects all body tissues,
fation of the diabetic HS sample, which again points to the Steno hypothesis assumes that this metabolic dysreg-
diabetes-induced undersulfation [207]. Culture of mes-
ulation of HS will also be found in other tissues than theangial cells on mesangial matrix that was nonenzymati-
kidney [214]. Indeed, immunohistochemical quantitationcally glycated or prolonged exposure of mesangial cells
of HS in skeletal muscle capillary BM [215] and in theto elevated glucose levels leads to a decreased produc-
dermal-epidermal junction of the skin of IDDM patientstion of HS, which, in addition, is undersulfated [208–210].
[216] clearly demonstrates a loss of HS staining in theseThis was also found after stimulation of mesangial cells
structures, analogous to our findings in the GBM. In thewith angiotensin II, which is assumed to be increased
STZ diabetes model in the rat, we found an associationin diabetes [211]. This undersulfation of HS could be
between an increase of the transcapillary passage of albu-due to a decreased activity of the enzyme glucosaminyl
N-deacetylase/N-sulfotransferase, the key enzyme in HS min and a decreased HS content in various tissues [217],
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